Press coverage about Integra Lifesciences (NASDAQ:IART) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Integra Lifesciences earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the life sciences company an impact score of 46.3167379351658 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Integra Lifesciences’ (IART) “Hold” Rating Reiterated at Barclays (americanbankingnews.com)
- Integra Lifesciences Holdings Corp (IART) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Integra LifeSciences Sees Q4 Revenue Above View (markets.businessinsider.com)
- Analyzing DENTSPLY SIRONA (XRAY) and Integra Lifesciences (IART) (americanbankingnews.com)
- Integra Lifesciences’ (IART) Neutral Rating Reaffirmed at Cantor Fitzgerald (americanbankingnews.com)
Shares of Integra Lifesciences (NASDAQ:IART) traded down $0.14 during midday trading on Tuesday, reaching $49.54. The company’s stock had a trading volume of 644,797 shares, compared to its average volume of 724,133. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. The company has a market cap of $3,890.00, a PE ratio of 81.21, a PEG ratio of 1.55 and a beta of 0.65. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $56.42.
IART has been the topic of several research reports. Zacks Investment Research downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Royal Bank of Canada restated a “sector perform” rating and set a $50.00 price objective (up from $48.00) on shares of Integra Lifesciences in a report on Thursday, November 9th. Oppenheimer set a $58.00 price objective on Integra Lifesciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. Barclays restated an “equal weight” rating and set a $53.00 price objective (up from $47.00) on shares of Integra Lifesciences in a report on Tuesday, September 12th. Finally, Wells Fargo & Co downgraded Integra Lifesciences from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company. Integra Lifesciences has an average rating of “Hold” and an average price target of $52.70.
In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now directly owns 55,540 shares in the company, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is currently owned by company insiders.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.